VBI Vaccines Reports Second Quarter 2023 Financial Results
PreHevbrio global net revenue increased 48% quarter-over-quarter from Q1 to Q2 2023 - redefined, highly targeted commercial field team deployed at the end of Q2 Expanded hepatitis B... -Today at 08:04 am- MarketScreener